Benchmark Holdings PLC's (LON:BMK) chairman Peter George speaks to Proactive London's Andrew Scott soon after agreeing to sell its vaccine manufacturing assets at its facility in Braintree, UK to Cell and Gene Therapy Catapult. George says he's pleased that Benchmark has been able to be part of the UK solution for vaccine manufacturing.
viewBenchmark Holdings PLC
Benchmark Holdings' Peter George says sale of its vaccine facility is a 'win-win-win'
Quick facts: Benchmark Holdings PLC
Price: 57.5 GBX
AIM:BMK
Market: AIM
Market Cap: £384.77 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Benchmark Holdings PLC named herein, including the promotion by the Company of Benchmark Holdings PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Benchmark sees long-term growth in aquaculture
Most read
Industry & services
Tesla shares tumble below level from before S&P 500 inclusion
4 days, 14 hours ago
Health
Coronavirus: Pfizer vaccine proves highly effective in real-world study,...
2 days, 17 hours ago
Mining
Condor Gold starts drilling at Cacao, the first step towards demonstrating...
5 days, 22 hours ago
